--- title: "REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM) | 8-K: FY2025 Q4 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/276937766.md" datetime: "2026-02-25T21:08:56.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/276937766.md) - [en](https://longbridge.com/en/news/276937766.md) - [zh-HK](https://longbridge.com/zh-HK/news/276937766.md) generator: "portal-rs" --- # REVOLUTION MEDICINES INC C/WTS 17/12/2026 (TO PUR COM) | 8-K: FY2025 Q4 Revenue: USD 0 Revenue: As of FY2025 Q4, the actual value is USD 0. EPS: As of FY2025 Q4, the actual value is USD -1.86. EBIT: As of FY2025 Q4, the actual value is USD -370.98 M. ### Financial Highlights for Q4 and Full Year 2025 #### Research and Development (R&D) Expenses - **Fourth Quarter:** R&D expenses increased to $294.9 million in Q4 2025 from $188.1 million in Q4 2024, driven by higher clinical trial and manufacturing expenses for daraxonrasib, zoldonrasib, and elironrasib, as well as increased personnel-related expenses and stock-based compensation due to additional headcount . - **Full Year:** R&D expenses increased to $987.3 million for FY 2025 from $592.2 million for FY 2024, primarily due to higher clinical trial and manufacturing expenses for daraxonrasib, zoldonrasib, and elironrasib, and increased personnel-related expenses and stock-based compensation . #### General and Administrative (G&A) Expenses - **Fourth Quarter:** G&A expenses rose to $66.7 million in Q4 2025 from $28.2 million in Q4 2024, mainly due to increased commercial preparation activities and personnel-related expenses, including stock-based compensation from additional headcount . - **Full Year:** G&A expenses increased to $195.0 million for FY 2025 from $97.3 million for FY 2024, mainly due to increased commercial preparation activities and personnel-related expenses, including stock-based compensation . #### Loss from Operations - **Fourth Quarter:** Loss from operations was - $361.626 million in Q4 2025, compared to - $216.310 million in Q4 2024 . - **Full Year:** Loss from operations was - $1,182.369 million for FY 2025, compared to - $689.524 million for FY 2024 . #### Net Loss - **Fourth Quarter:** Net loss totaled - $364.9 million in Q4 2025, an increase from - $194.6 million in Q4 2024 . - **Full Year:** Net loss totaled - $1.1 billion for FY 2025, compared to - $600.1 million for FY 2024 . #### Interest Income - **Fourth Quarter:** Interest income was $21.292 million in Q4 2025, compared to $21.225 million in Q4 2024 . - **Full Year:** Interest income was $90.694 million for FY 2025, compared to $86.883 million for FY 2024 . #### Interest Expense - **Fourth Quarter:** Interest expense was - $11.936 million in Q4 2025, compared to $0 in Q4 2024 . - **Full Year:** Interest expense was - $24.231 million for FY 2025, compared to $0 in FY 2024 . #### Change in Fair Value of Warrant Liability and Contingent Earn-out Shares - **Fourth Quarter:** This change was - $12.627 million in Q4 2025, compared to - $0.017 million in Q4 2024 . - **Full Year:** This change was - $15.358 million for FY 2025, compared to $4.323 million for FY 2024 . #### Other Income (Expense), Net - **Fourth Quarter:** Other income (expense), net was $0.005 million in Q4 2025, compared to - $0.220 million in Q4 2024 . - **Full Year:** Other income (expense), net was - $0.037 million for FY 2025, compared to - $2.528 million for FY 2024 . ### Balance Sheet Highlights as of December 31, 2025 vs. 2024 #### Cash, Cash Equivalents and Marketable Securities - This balance stood at $2,025,679 thousand in 2025, down from $2,289,299 thousand in 2024 . This figure includes a $250 million royalty monetization tranche received in June 2025, with an additional $1.75 billion in future committed capital under the arrangement with Royalty Pharma . #### Working Capital - Working capital was $1,784,613 thousand in 2025, compared to $2,163,718 thousand in 2024 . #### Total Assets - Total assets were $2,354,508 thousand in 2025, compared to $2,558,301 thousand in 2024 . #### Total Liabilities - Total liabilities were $723,211 thousand in 2025, compared to $293,097 thousand in 2024 . #### Total Stockholders’ Equity - Total stockholders’ equity was $1,631,297 thousand in 2025, compared to $2,265,204 thousand in 2024 . ### 2026 Financial Guidance Revolution Medicines anticipates full year 2026 GAAP operating expenses to be between $1.6 billion and $1.7 billion, which incorporates an estimated non-cash stock-based compensation expense ranging from $180 million to $200 million . The company plans to continue advancing its broad late-stage pipeline with five ongoing Phase 3 trials and three additional Phase 3 trials planned to initiate in 2026 . **Note:** Segment revenue, gross margin, operating margin, operating cash flow, and free cash flow were not explicitly provided in the reference text . ### Related Stocks - [RVMDW.US](https://longbridge.com/en/quote/RVMDW.US.md) ## Related News & Research - [Nvidia Just Delivered Bad News for AMD and Intel](https://longbridge.com/en/news/297432140.md) - [The Calmer Co. Details ASX Governance Compliance in Appendix 4G Filing](https://longbridge.com/en/news/297454626.md) - [Bilibili: Buy Rating Backed by Resilient Growth, Operating Leverage, and Attractive Valuation](https://longbridge.com/en/news/297434042.md) - [PRECIOUS-Gold dips as Fed hike bets rise, still heads for best month since Jan](https://longbridge.com/en/news/297488642.md) - [Xpeng GX reaches 20,000 deliveries just over 3 months after launch](https://longbridge.com/en/news/297473414.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**